To support preclinical and clinical development programs, ERBC conducts PK-PD and metabolism studies on pharmaceuticals and biotechnology based products.
Conducted in a broad range of administration routes, dosing regimens and animal species, these studies are managed by senior scientists with deep expertise in biology, pharmacology, data analytics and regulatory.
Pharmacokinetic – bioavailability
- Species: rat, mouse, rabbit, dog, minipig, marmoset
- All administration routes
- Analysis of biological samples (plasma, urine, tissues…)
Pharmacodynamic in vivo and in vitro
- Deep expertise in human recombinant proteins, notably GSCF, hGH and EPO (in vivo)
In vitro metabolism
- Evaluation of metabolism using liver metabolic fractions (S9, microsomes)
- Evaluation of metabolism using hepatocytes
- Metabolite profiling, identification and quantification
- CYP phenotyping assay
- CYP induction in human hepatocytes
- CYP inhibition in human liver microsomes
- Time dependent CYP inhibition in human liver microsomes
Skin Penetration Study
- In vitro Skin Absorption (OECD 428)
Histochemical and immunohistochemical determinations in tissues
- Cytochrome p450
- Glutathion S-transferase
- γ-Glutamyl transpeptidase
- Cytochrome oxidase
- Adenosine triphosphatase
- Glucose-6-phosphate dehydrogenase
